Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)

NCT05061550 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05061550
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05061550 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Recruiting
Start date
April 14, 2022
Completion date
May 28, 2030
Enrollment
630 (estimated)
Sites
97

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer